Автореферат и диссертация по медицине (14.00.10) на тему:Апоптоз лимфоцитов периферической крови при вирусных гепатитах А, В, С у детей и влияние на него препаратов урсодеоксихолевой кислоты

СПИСОК СОКРАЩЕНИЙ.

ВВЕДЕНИЕ.

ЧАСТЬ I. ОБЗОР ЛИТЕРАТУРЫ.

ГЛАВА 1. АПОПТОЗ И ЕГО РОЛЬ В ПАТОГЕНЕЗЕ ВИРУСНЫХ

ГЕПАТИТОВ.

ГЛАВА 2. УРСОДЕОКСИХОЛЕВАЯ КИСЛОТА (УДХК) И ЕЁ

ПРИМЕНЕНИЕ ПРИ ВИРУСНЫХ ГЕПАТИТАХ

ЧАСТЬ II. СОБСТВЕННЫЕ ИССЛЕДОВАНИЯ.

ГЛАВА 3. ПАЦИЕНТЫ И МЕТОДЫ.

3.1 Клиническая характеристика обследованных больных.

3.1.1. Состав обследованных больных.

3.1.2. Клиническая характеристика острых гепатитов А и В.

3.1.3. Клиническая характеристика хронических гепатитов В и С.

3.2. Методы обследования.

3.2.1. Базовые методы обследования.

3.2.2 Методы тестирования маркеров вирусов А, В, С.

3.2.3. Дополнительные методы обследования.

3.2.4. Специальные методы исследования.

3.2.5 Исследование состояния апоптоза лимфоцитов периферической крови (ЛПК) у здоровых детей.

3.2.6. Дизайн исследования.

3.2.7 Статистическая обработка результатов.

ГЛАВА 4. АПОПТОЗ В ПАТОГЕНЕЗЕ ОСТРЫХ ВИРУСНЫХ

ГЕПАТИТОВ АИВ.

4.1. Соотношение апоптоза ЛПК с этиологией, тяжестью и течением вирусных гепатитов.

4.2. Связь апоптоза ЛПК и биохимических показателей при вирусных гепатитах.

4.3. Влияние на показатели апоптоза ЛПК пола, возраста, неблагоприятного преморбидного фона и интеркуррентных заболеваний.

ГЛАВА 5. АПОПТОЗ ЛПК В ПАТОГЕНЕЗЕ ХРОНИЧЕСКИХ ВИРУСНЫХ ГЕПАТИТОВ.

5.1 Показатели апоптоза ЛПК при хроническом течении гепатитов В и С.

5.2 Соотношение апоптоза ЛПК с вирусной репликацией.

5.3 Соотношение апоптоза ЛПК с билирубином и цитолизом.

5.4 Влияние на показатели апоптоза ЛПК пола и возраста.

5.5 Апоптоз ЛПК и сопутствующая патология у больных

ХГВ и С.

ГЛАВА 6. ВЛИЯНИЕ УРСОДЕОКСИХОЛЕВОЙ КИСЛОТЫ НА АПОПТОЗ ЛПК ПРИ ВИРУСНЫХ ГЕПАТИТАХ.

6.1. Влияние препарата урсодеоксихолевой кислоты на апоптоз

ЛПК и течение острых вирусных гепатитов.

6.2. Влияние препарата урсодеоксихолевой кислоты на апоптоз

ЛПК при затяжном течении вирусного гепатита А.

6.3. Влияние препарата урсодеоксихолевой кислоты на апоптоз

ЛПК при хронических гепатитах В и С.

1. Аммосов А.Д. Гепатит В Аналитический обзор. Институт средств медицинской диагностики ЗАО «Вектор-бест». // г.Кольцово, 2005г.- 127с.

2. Баранов А.А, Каганов Б.С, Учайкин В.Ф. и авторский коллектив Диагностика и лечение хронических вирусных гепатитов В, С, Д у детей.// Пособие для врачей. Министерство Здравоохранения РФ. 2003г.-84с.

3. Баранов А.А, Шиляев P.P., Каганов Б.С. Избранные лекции по педиатрии.// М.:Издательский Дом «Династия»,2005г.- 640с.

4. Белушкина Н.Н., Хасан Хамад Али, Северин С.Е. Молекулярные основы апоптоза.// Ж. Вопросы биол.мед. и фарм. Химии, 1998г., № 4, с. 15-23

5. Владимирская Е.Б., Казначеев К.С., Осипова Е.Ю. Мониторинг апоптозалейкоцитов периферической крови в норме и у детей, перенесших острыйлимфобластный лейкоз.// Ж.Гематологии и трансфузиологии, 2001г., т.46, №4,с.24-27

6. Выставкина Г.В, Писарев А.Г, Учайкин В.Ф, Чаплыгина Г.В. Лечение Урсосаном холестаза при острых и хронических вирусных гепатитах у детей.// Ж . Детские инфекции. 2002г., г.М., №1,с. 40-42

7. Горошанская М.Н., Чередниченко Т.В., Николаева Л.И., Молочкова О.В., Учайкин В.Ф. Клиническое значение определения антител к различным антигенам HCV у детей первого года жизни. // Ж. Детские болезни, г.М., 2005г., №2, стр.11

8. Дмитриева Е.В. Роль апоптоза в патогенезе заболеваний печени различной этиологии. // Диссертация канд.биол.наук, г.М., 2003г.

9. Змызгова А.В., Москалёва Е.Ю., Максимов С.Л. и др. Структура ДНК лейкоцитов периферической крови и показатели клеточного иммунитета больных вирусным гепатитом.// Ж.Вопросы биологической, медицинской и фармацевтической химии. 1999г, г.М., №2, с.16-19

10. Иванова В.В. Инфекционные болезни у детей. // Учебное пособие. М.гООО «Мед.Информ.Агенство»,2002г.- 928с.

11. Ивашкин В.Т. Комбинированное лечение хронического гепатита В.// Росс.журн.гастроэнтерологии, гепатологии, колонопроктологии. М., 1998г. №5, с.57-60

12. Ивашкин В.Т., Буеверов А.О. Лечение больных с первичным билиарным циррозом печени.// Ж. Аутоиммунные заболевания печени в практике клинициста. М.: Издательство Дом «М-Вести», 2001 г.-102с.

13. Капустина Т.Ю., Каширская Н.Ю., Неудахин Е.В, Капранов Н.И. Длительное применение урсодеоксихолевой кислоты при поражении печени у больных муковисцидозом.// Росс. Гастроэнтерол. журнал, М.,2000г.,№2,с.61-67

14. Котович М.М. Роль этиотропной и патогенетической терапии в клинической и морфологической эволюции хронических гепатитов у детей.//Автореф.дисс.докт.мед. наук, М, 2003г.

15. Кузнецов В.В. Лечение хронических гепатитов урсосаном.// Ж. Terra Medica/-1997,№ 1 .С.40-41

16. Лазебник Л.Б., Ильченко Л.Ю, Голованова Е.В. Урсодеоксихолевая кислота. К 100-летию обнаружения.// Ж. Консилиум Медикум. №6, т.4. М., 2002г., с.324-6

17. Лобзин Ю.В., Жданов К.В,. Волжанин В.М,. Гусев Д.А. Вирусные гепатиты: клиника, диагностика, лечение. // Санкт-Петербург, ООО «Издательство Фолиант»,2003г.-192с.

18. Лупашко ЮА. Эффективность сочетанной терапии интерфероном и УДХК у больных хроническим вирусным гепатитом С.// РЖГГК №1. 2005. тезис 61.

19. Маевская М.В. Алкогольная болезнь печени.// Ж. Консилиум Медикум, т.З, №6, 2001г., с.256-60

20. Маянский А.Н., Маянский Н.А. и др. Апоптоз: начало будущего.//Журнал микробиологии, г.М.,1997г., №2, с.88-94

21. Михайлов М.И, Семененко Т.А, Максимов В.А. УДХК в лечении хронических гепатитов(моно-и комбинированная терапия с препаратами интерферона). // Ж. Гепатология и гастроэнтерология, г.М, 1994,№2.с. 16-26

22. Надинская М.Ю. Исследование применения урсодеоксихолевой кислоты в гепатологии с позиции медицины, основанной на научных доказательствах.// Ж.Консилиум медикум,том 5, №6, 2003г., 5с.

23. Новиков B.C., Цыган В.Н. Физиологические аспекты апоптоза.// Росс.Физиол.Журн. им. Сеченова И.М. №4;с. 13-23

24. Поспелова Т.И., Лосева М.И., Агеева Т.А., Маслова Л.М., Солдатова Г.С. Препарат Урсосан в лечении синдрома холестаза у больных гемобластозами в отдалённом периоде клинико- гематологической ремиссии.// Ж. Росс. Гастроэнтерологии, №1, 2000г.,с.63-9

25. Проскуряков С.Я., Габай В.Л., Коноплянников А.Г. Некроз активная управляемая форма программируемой клеточной гибели.// Ж.Биохимия, 2002г, т.67, вып.4, с.467-491

26. Рейзис А.Р. Терапия и профилактика хронических гепатитов В и С у детей и подростков.// Сб. Современные проблемы профилактической педиатрии: диагностика, лечение и профилактика хронических вирусных гепатитов В, С и Д у детей. М.,2003г., с.6-8

27. Рейзис А.Р. Лечение хронического гепатита С у детей и подростков интерфероном а -2а.// Ж. Вопросы современной педиатрии, г.М., 2002. №1. Т.1 С. 17-22

28. Рейзис А.Р., Дрондина А.К., Никитина Т.С., Ананьева Н.П., Стулов А.П., Загузова Л.И., Иванчатенко Г.Н. Урсодеоксихолевая кислота в лечении острых и хронических вирусных гепатитов у детей.// РГЖ, 1999г, №.4, с.44-49

29. Рейзис А.Р., Дрондина А.Н., НикитинаТ.С. и др. Комплексная терапия хронического гепатита С у детей и подростков.// Ж. Вопросы современной педиатрии, г.М., 2004г., том 3, прилож.З, с.80

30. Рейзис А.Р., Никитина Т.С., Дрондина А.С. и др. УДХК как фоновая терапия заболеваний гепатобилиарной системы у детей и подростков.// Сб.статей «Новые возможности в лечении заболеваний печени.» М., 2002г., с.54

31. Рейзис А.Р., Нурмухаметова Е.А. Вирусные гепатиты у детей с онкогематологическими заболеваниями.// Ж.Медицина для всех. №1, 1996.С.24-27

32. Рейзис А.Р., Матанина Н.В., Шмаров Д.А. Апоптоз в патогенезе синдрома холестаза и возможности его коррекции.// Материалы XI1 Конгресса Актуальные проблемы абдоминальной патологии. М, 2005г.

33. Топорков А.С. Применение УДХК при хронических вирусных гепатитах//. Ж.Консилиум медикум приложение, том 6, №3, 2004г., с.9

34. Турьянов М.Х, Алленов М.Н, Сапронов Г.В. и др. Использование урсосана в терапии острых вирусных гепатита.// Сборник тезисов V Российского съезда врачей-инфекционистов. М, 15-17декабря 1998.-С.48

35. Турьянов М.Х., Федосеев М.А. Применение урсодеоксихолевой кислоты при вирусных гепатитах.// Росс.Гастроэнтерол.Журн. 1999. М.,№ 2. С.72-75

36. Учайкин В.Ф., Конев В.А., Каганов Б.С. //Иммуноферментный анализ при вирусных гепатитах у детей. //Ж. Эпидемиологии и инфекционные болезни 1996г., №1, стр.44-49

37. Цыган В.Н. Актуальные проблемы иммунологии.// СПб., Гуманистика, 2004.- с. 47

38. Чередеев А.Н., Ковальчук JI.B. Апоптоз как важный этап оценки иммунной системы по патогенетическому принципу.// Клин.лаб.диагностика (1997) 7, с.31-35

39. Чубенко С.С, Мальцева Н.В, Чубенко Д.С, Гайдуков В.О. Эффективность лечения неалкогольного стеатогепатита.// РТГК, прил.24 материалы X Российской конференции «Гепатология сегодня», г.Москва 28-30 марта 2005г, стр.56

40. Шептулин А.А. Новые данные о применении урсодеоксихолевой кислоты при лечении заболеваний печени. //Ж. Гастроэнтерологии, гепатологии, г.М.,2000г.,№ 4, с.24-25

41. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей.// М:Гэотар Медицина,2002.С.31, с.254

42. Шмаров Д.А.,Козинец Г.И. Лабораторно-клиническое значение проточно-цитометрического анализа крови.//М.'.Медицинское информационное агенство, 2004.-128 с.:ил.

43. Ярилин А.А. Апоптоз и его место в иммунных процессах.// Ж.Иммунология, г.М., 1996г., т.6,с. 10-23

44. Abdelmalek M.F, Harrison М.Е, Gross J.B Jr, Poterucha J.J,Gossard AA,Spivey J.R, Rakela J, Lindor K.D. Treatment of chronic hepatitis С with interferon with or UDCA:a randomised prospective trial.// L Clin Gastroenterol. 1998. Mar;26(2): 130-4

45. Abe S, Kotoh K, Arao S, Tabaru A, Otsuki M. Fas antigen expression on hepatocytes predicts the short-and long-term response to interferon therapy in patients with chronic hepatitis С.// Scand J Gastroenterol.2001 Mar; 36(3): 326-31

46. Adachi M., Suematsu.S., Suda T. et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. //Proc.Natl.Acad.Sci.USA 1993: 21

47. Alenezi В, Lamoureux E, Alpert L, Szilagyi A. Effect of UDCA on granulomatous liver disease due to sarcoidosis.// Dig D IS Sci 2005,Jan;50(l): 196200

48. Anan A, Baskin-Bey E.S, Bronk S.F, Werneburg N.W, Shah V.H, Gores G Proteasome inhibition induces hepatic stellate cell apoptosis.// J Hepatology. 2006 Feb;43(2):335-44

49. Anatol P, Danuta P, Janusz D, Bozena P. Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy.// Epub 2005 Feb 15 World J Gastroenterol. 2005 May 21;ll(19):2949-52

50. Anderson D.A., Ross B.C., Locarnini S.X. Restricted replication of hepatitis A virus in cell culture: encapsidation of viral RNA depletes the pool of RNA available for replication. //J. Virol. 1988. Nov.62 (11): 4201-6

51. Angelico M, Gandin C, Pescarmona E. et al Recombinant interferon-alpha and UDCA versus interferon-a alone in the treatment of chronic hepatitis C:a randomized clinical trial with long-term follow-up.// Am J Gastroenterology. 1995 Vol.90. P.263-269

52. Askenazi A., Dixit V.H. SODD/TNFR-1 signaling Pathway. //J.Science. 1998. Dec;34(10) :2801-1

53. Attili AF., Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile-acid-induced liver toxicyty: relation to the hydrophobic-hydrophilic balance of bile acids.// Med Hypotheses 19,1986, p.56-69

54. Azzoroli F, Mehalw, Soroka C.I, Wang L, Lee J, Crispe N, Boyer J.L. UDCA diminishes Fas-ligand induced-apoptosis in mouse hepatocytes.// J Hepatology 36(1) 2002,49-54

55. Bachrach W.H, Hofmann A.F. UDCA in the treatment of cholesterol cholelithiasis.//Dig Dis Sci. 1982; 27:737-61

56. Balestreri W.F, Setchell K.D, Ryckman F.C, and the UDCA study Group. Bile acid therapy in pediatric liver disease.// In:Paumgartner G.,Stiehl A,Gerok W eds: Bile Acids and the Hepatobiliary System.London: Kluwer Academic Publishers, 1993:271-82

57. Balistreri W.F. Bile acid therapy in pediatric hepatobiliary disease the role of UDCA .// J Pediatr Gastroenterol Nutr. 1997, May,24(50:573-89

58. Banner D.W. et al. Apoptosis. //J Cell. 1993,73:431

59. Berger A.,Braner G.,Doer H.W., Weber B. Quantification of Viral Load: Clinical Relevance for Human Immunodeficiency Virus, Hepatitis В Virus and Hepatitis С Virus Infection.// Intervirology, 1998, 41, 24-34.

60. Belliveau P.P, Nightingale C.H., Qunitiliani R., Maderazo E.C. Reduction in serum concentrations of ciprofloxacin with hepatobiliary disease.// Clin Infect Dis 1994: 19:354-5

61. Ben-An Z., Schmilovotz-Weiss H., Belinki A. et al. Circulating soluble cytochrome С in liver disease as a marker of apoptosis//. J. of Internal Medicine Vol. 254 Issue 2. P. 168. August.2003

62. Benedetti A., Jezugel A, Oriandi M. Preferential distribution of apoptosis bodies in acinar zone 3 of normal human and rat liver. //J.Hepatol.-1988-7-P.319-324

63. Berke G. Killing mechanisms of cytotoxis lymphocyte.// Curr Opin Hematol. 1997, 4:32-40

64. Beuers U, Fischer S., Spengler U., Paumgartner G. Formation of iso-ursodeoxycholic acid in man.// J Hepatol 1991:13:97-103

65. Beuers U, Nathanson M.H, Bayer I.L. Effects of tauroursodeoxycholic acid on cytosolic Ca-signals in isolated rat hepatocytes.// J Gastroenterology 1993; 104:60412

66. Beuers U, Spengler U, Kruis W. Ursodeoxycholic acid for treatment of primary sclerosing cholangitidis: a placebo-controlled trial.// J Hepatology; 1992:16:707

67. Beuers U, Spengler U, Zwiebel F.M, Paulezki J, Fischer S, Paumgartner G. Effect of UDCA on the major hydrophobic bile acids in health and in chronic cholestasis liver disease.// J Hepatology 1992; 15:603-8

68. Bittner P. Pathologie des hepatobiliaren Systems bei Mucoviszidose und therapeutishe Ansatze// In H.Lindenmann (Hrsg): CF-Symposium Giezen 1988: Fortschritte in Diagnostic und Therapie der Mucoviczidose, 105-113

69. Boucher E. Interferon and UDCA combined therapy in the treatment of chronic hepatitis C: Resalts from a controlled randomized trial in 80 patients. // J Hepatology-1995 .Vol.21. №2, p.322-326

70. Brack K., Berk Y., Magilski T. Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double- stranded RNA.// J.Virol 2002 Dec. 76(23): 11920-30

71. Buzzeli G, Moscarella S, Focardi G. UDCA in the treatment of chronic active hepatitis A controlled clinico-therapeutic study.// Minerva Med. 1992;83:537-40

72. Calmus Y, Guechot J, Podevin P, Bonnefis M, Giboudeau J, Poupon R Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleikin 1, production by monocytes.// J Hepatology 1992,16;719-23

73. Cardin R., Derrico A., Florentino M. et al. Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-relation liver disease. // J Medical Councilon Alcohol. Vol.37, NQ.l,p.43-48,2002

74. Caroli-Bosc F.X, Iliadis A, Salmon L. et al. UDCA modulates cyclosporin A oral absorbtion in liver transplant recipients.// Fundam Clim Pharmocol 2000:14:6019

75. Castiella A, Jribarren J.A, Lopez P, Arrizobalaga J, Rodrigues F, von Wichmann M.A, Arenas J.I. UDCA in the treatment of AIDS-associated cholangiopathy. // Am J Med 1997,Aug; 103(2):170-1

76. Castro R.E., Amaral J.D., Kren B.T., Steer C.J., Rodrigues C.M.P. UDCA modulates cell cycle proteins that control apoptosis of primary rat hepatocytes. // J of Hepatology, Vol.42, Suppl. 2, p. 104.Apr.,2005, Paris

77. Chan C.W., Gunsar F, Feudjo M, Rigamonti C, Via Chogiannakos J, Carpert J.R., Burroughs A.K. Long-term UDCA therapy for primary biliary cirrhosis: a follow up to 12 years. // Aliment Pharmacol Ther 2005;21:217-226

78. Chazouilleres O, Poupon R, Capron J.P. et al. UDCA for primary sclerosing cholangitidis.// J Hepatol 1990; 11:120-3

79. Chen G.Y, He J.Q, Lu G.C, Li M.W, Xu C.H, Fan W.W, Zhou C, Chen Z. Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitisB. // World J Gastroenterol. 2005 Jul 14; 11(26):4090-3

80. Chen W, Liu Y, Glund C. Bile acids for viral hepatitis , 2003.// Cochrane Database Syst Rev 2003, (2):CD 003181

81. Cheng Y, Tauschel H.D, Nilsson A, Duan rd. UDCA increases the activities of alkaline sphingomyelinase and caspase03 in the rat colon.// Scadinavian J of Gastroenterology 34(9) 1999, 915-920

82. Chevrel B. Acide ursodeoxycholigue,cirrhose biliare primitive,cholangite sclerosante primitive, et mucoviscidose.// Med Chir Dig. 18(5), 285-289

83. Chisary F.V. Viruses, immunity and cancer: lesson from hepatitis В.// Am J. Pathol. 2000, 156(4). p.l 118-1132

84. Chizari F.V., Ferrari C. Hepatitis В virus immunopathogenesis.// Annu Rev Immunol. 1995,13.29-60

85. Chretien Y, Poupon R, Gherardi M.F. et al. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis:effect of ursodeoxycholic treatment.// Gut, 1989;30:1110-5

86. Clarke В. Molekular virology of Hepatitis С virus. // J. Gen.Virol. 1997,78:2397-2410

87. Coga H., Sakisaka S., Ohiski M. et al. Nuclear DNA fragmentation and expression of bcl-2 in primar biliare cirrosis. // Hepatol 1997,25,p.l077-1084

88. Colombo C, Gjunta A, Podda M, Crosignani A, Zimmer-nechemias L, Setchell KDR. The effect of ursodeoxycholic acid on liver function and bile acid metabolism in patients with cystic fibrosis and liver disease.// Hepatology 10(4) 1989,726,a-632

89. Colombo C. Cholestatic liver disease in children.// In Falk Symposium №75»Cholestatic liver disease: Kluwer Academic Press, London 1994, 154-163

90. Columbano A., Leddo-Columbano G.H., Com.G. et al. Occurrence of cell death(apoptosis) during the involution of liver hyperplasia.// Lab.Invest.-1985-51-p.670-675

91. Coste T, Bodin M, Dellatolas F. Efficacy of UDCA in the treatment of duodenogastric reflux in the antrectomized patients.// J Gastroenterology Clin В IOL 1991; 15;(8~9) 656-7.French

92. Crosignani A, Battezzati P.M., Setchell K.D.R et al. Effects of UDCA in serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose response study.// J Hepatology 1991,13:339

93. Czaja A.J, Carpenter H.A, Lindor K.D UDCA as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. // J Hepatology 30(6) 1999,1381-1386

94. De Caesteker J.S., Iazrawi R.P., Petroni M.U. et al. Ursodeoxycholic acid in chronic liver disease.// Cut.1991. Vol.32. P.1061-1065

95. Delich P, Hofman C.M, Luketic V.A. Treatment of chronic hepatitis C(HCV) with ursodeoxycholic acid (UDCA) in patients who failed interferon therapy. // Gastroenterology 1995;108;1057A

96. Doughty L, Clark R.S., Kaplan S.S, Sasser H, Carcillo J. SFas and sFas-L and pediatric sepsis — induced multiple organ failure syndrome. // Pediatr Res 2002 Dec; 52 (6): 922-7

97. Dumont M, Erlinger S, Uchman S. Hypercholeresis induced by UDCA and 7-ketoliticholic acid in the rat: possible role of bicarbonate transport.// J Gastroenterology 1980; 79:82-9

98. Earnest D.L, Holubec H, Wali R.K, Jolly C.S, Bissonette M, Bhattacha Lyya,Roy H, Khare S, Brasitus T.A. Chemopreventon of azoxymethane-induced colonic carcinogenesis by supplemental dietary UDCA.// Cancer R ES 1994 Oct l;54(19):5071-4

99. Fabris P, Tositti G, Mazzella G, Zanetti A.R, Nicolin R, Pellizzer G, Benedetti P. Effect of UDCA administration in patients with acute viral hepatitis: a pilot study .//Aliment Pharmacol Ther 1999; 13:1187-1193

100. Fan X.G., Liu W.E., Li C. et al. Circulating TH1/TH2 cytokines in patients with hepatitis С virus infections.// Mediators Jn flamm. 1998.7,p.297-298

101. Farinati F., Cardin R., Fiorentino M., D'Errico A., Grigioni W., Cecchetto A., Naccarato R. Imbalance between cytoproliveration and apoptosis in hepatitis С virus related chronic liver disease.// J Viral Hepatitis Vol.8 Issue 1 Page 34 Jaunuary 2001

102. Fedorowski T.L, Sale G, Callalilo A, Tint G.S, Mosbach E.H, Hall J.C. Metabolism of ursodeoxycholic acid in man. // J Gastroenterology, 1977;73:1131-7

103. Feitelson M.A, Reis H.M, Liu J, Lian Z, Pan J. Hepatitis В virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. //Front Biosci. 2005 May l;10:1558-72

104. Feldman G. Liver apoptosis.// J.Hepatologi-1997-22. P.l-11

105. Fischer M.M, Paradine M.E. Influence of UDCA on biochemical parameters in cholestatic disease.// J Gastroenterology 1986;90;1725

106. Fitz I. Ursodeoxycholate increase cytosolic calcium concentration and activates chlor-anion currents in billiary cell line.//Gastroenterology 1995;109:965-72

107. Foo N.C, Ahn B.Y, Ma X. Cellular vacuolization and apoptosis induced by hepatits В virus large surface protein. //Hepatology 2002 DEC 36/6

108. Foster G.R. Apoptotic cell death: the caspase cleavage "gold ruch". //Lancet 2005 Apr.-9-15;365 (9467):1293-4

109. Friman S, Svanik J. A possible role of UDCA in liver transplantation.// Scand J Gastroenterol. 1994; 29(suppl);62-4

110. Fromm H, Sarva R.P, Bazzoli F. Formation of UDCA from chenodeoxycholic acid in the human colon: studies of the role of 7-ketolithocholic acid as an intermediate.// J Lipid Res 1983;24:841-53'

111. Fujisawa, Kimura A, Ushijima K, Nakashima E, Inoue T, Yamashita Y, Kato H. Intestinal absorption of UDCA in children and adolescent with inflammatory bowel disease.// J of Pediatric Gastroenterology and Nutrition 26(3)1998,279-285

112. Galle P.R, Theilmann L, Raedsch R. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.// J Hepatology 1990;12:486-91

113. Galsky J, Bansky G, Holubova T, Konig G. Effect of ursodeoxycholic acid in acute viral hepatitis.// J Clin Gastroenterol. 1999;Apr;28(3):249-53

114. George R., Stevens A, Berkenbosch I.W, Turpin I, Tobias I. UDCA in the treatment of cholestasis and hyperbilirubinemia in pediatric intensive care unit patients.// J South Med 2002 Nov; 95(11): 1276-9

115. Gerber M.A. Pathologic effects of hepatitis CM J. Hepatol.-1995-22-P.83-86

116. Gilder M.A, Gann M.E, Opekun A.R, Gleason WA. Efficacy of UDCA in the treatment of primary sclerosing cholangitidis in children.// J of Pediatric Gastroenterology and Nutrition 31(2) 2000, 136-141

117. Gores G. Mechanisms of cell injuri and death in cholestasis and hepatoprotecton by UDCA.// J Hepatol 2000; 32( suppl. 2):11-3

118. Gottrand F. "Role de l'acide ursodesoxycholique dans le traitement des cholestases de 1'enfant." Gastroenterol.Clin.Biol. 2004; 28:852-859

119. Gricciardi M.E, Gores G.J. Apoptosis: a mechanism of acute and chronic liver injury.// Gut 2005 Jul; 54 (7); 1024-33:

120. Griffith T.H, Brunner T, Fletcher S.M et al. Fas-ligand-induced apoptosis as a mechanism of immune privilege.//Science 1995;270:1189-92.

121. Grovatto M., Rozatto G. et al. Periferal blood neutrofils from hepatitis С virus infected patients are Replication sites of the virus.// J Hematologica,2000,85(40,356-361

122. Gowans EJ. Distribution of markers of hepatitis С virus infection throughout the body. //Semin Liv Dis. 20 (1), 85-102 (2000)

123. Guicciardi M.E, Gores G.I. Is ursodeoxycholic acids an antiapoptotic drug?//Hepatology 1998;28:1721-3

124. Guldutuna S, Kurtz W, Pelecanos C, Zimmer G, Leuschner U. Mechanismen von membransschadigung und membranscgutz durch Gallensauren. // In: W.Kurtz (Hrsg): Gallensauren und MagenDarmtract, Verlag Htgieneplant Gmbh, Oberusel, 1988, 19-29

125. Guldutuna S, Zimmer G, Imhof M, Bhatti S, Tiangeng Y, Leuschner U. Molecular aspekts of membrane stabilisation by ursodeoxycholate.//J Hepatology, 1993; 104:1736-44

126. Harnois D.M, Angulo P, Jorgensen R.A, La Russo N.F, Lindor K.D. High-dose UDCA as a therapy for patients for patients with primary sclerosing cholangitidis.// Am J Gastroenterology 2001; 96:1558-62

127. Hayakawa T, Hachiya H, Katagiri K, Hochino M, Yoshika N, Kawanura Y, Takeshima A. et al. Effect of bile acids on cholestasis induced by 17-ethinil estradiol.// ( in Iapan) Acta HEPATOL Ipn.28(l 0)1987,1354-1360

128. Hayashi N., Mita E. Fas system and apoptosis in viral hepatitis.// J.Gastroenterol hepatol.l997.0ct.l2(9-10):S 223-6

129. Hayashi N., Mita E. Involvement of FAS-system-mediated apoptosis in patogenesis of viral hepatitis.// J Viral Hepat.1999 sep,6(5):357-652

130. He J, Nakao H., Tan SI. et al. Subversion of cell signaling pathways by hepatitis С virus non structural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.// J.Virol 2002 Sep,76(18):9207-17

131. Hempeling W, Dilger K, Beuers U. Systematic review: udca-adverse effects and drug interactions.// Aliment Pharmacol Ther 2003; 18:963-972

132. Heuman D. Hepatoprotective pripeties of UDCA.// J Gastroenterol 1993;104:1865-70

133. Heuman D.M, Mills A.S, Mc Call J. et al. Conjugates of ursodeoxycholate protect against cholestasis and hepato-cellular necrosis caused by more hydrophobic bile salts.// In vivo studies in the rat.J Gastroenterology, 1991;100:203-11

134. Hoffman A.F. Strategies vor the hepatobiliary Disease.// Eds. G.Paumgartner et al.Dordrecht. 1990. P-13-33

135. Hofman A.F. Bile acid secretion, bile flow and biliary lipid secretion in humans.//J Hepatology, 1990; 12;P.17

136. Hofman A.F. Pharmacology of UDCA an enterohepatic drug.// Scand J Gastroenterology Suppl. 1994:204:1-15

137. Hofmann A.F., Barrett K.E,.Ouist R.G. Mechanisms of action of UDCA in the treatment of chronic cholestatic hepatobiliary disease: experiments and speculations.// Abstr. Falk SymposiunN053; J Int Lugano Symposium, Iune 15-17, 1989,17

138. Hou W., Liu K.Z, LiM W, Wo J.E. Effect of INF alpha-2a on Fas expression and apoptosis rate of peripheral blood cytotoxic T-cells in patients with hepatitis В.// Hepatobiliary Pancreat Dis Int. 2005 Aug.;4(3):403-5

139. Howard P.J, Murphy G.M. Bile acid stress in the mother and baby unit.// European J of Gastroenterology and Hepatology 15(3).2003,.317-321

140. Hsu H., Xiong I., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-karr В activation.// Cell. 1995,81,495-504 (Vedline) Order article via Jnfotrieve

141. Ichiki Y, Aoki C.A, Bowlus C.L, Shimoda S, Ishibashi H, Gershwin M.E. T-cell immunity in autoimmune hepatitis. //Autoimmun Rev. 2005 Jun;4(5):315-21

142. Ikegami T, Matsuzaki Y, Al Rashid M, Ceryak S, Zhang Y, Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. // Mol Cancer Ther. 2006 Jan;5(l):68-79

143. Iwasaki T. Uber die Konstitution der Ursodeoxycholsaure.// Z Physiol Chemm 1936;244:181-93

144. Jazrawi R.P, De Caestecker J.S, Goggin P.M, Britten A.J, Joseph A.E.A, Maxwell I.D et al. Kinetics of hepatic handling in cholestatic liver disease: effect of UDCA.// J Gastroenterology 1993; 106:134-42

145. Jia X.Y., Tesar M., Summers D.F., Ehrenfeld E. Replication of hepatitis A viruses with chemeric 5nontransleted regions. //J.Virol. 1996 May, 70(5):2861-8

146. Kadayifci A, Savas M.S, Arslan S, Gullu I.H. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B.// J Clin Gastroenterol 1997;24:125-6

147. Kallinowski B, Theilmann L, Zimmermann K, Gams E, Kommerell B, Stiehl A. Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid.// Transplantation 1991 ;51:1128-9

148. Kam P.C., Ferch N.J. Apoptosis: mechanisms and clinical implications.// Anaesthesia-2000-55.p. 1081 -1093

149. Kato N, Yoshida H, Kioko Ono-Nita S. et al. Activation of intracellular signaling byhepatitis В and С viruses: C-viral core is the most potent signal inducer//Hepatology 2000,32(2), 405-412;

150. Keiding S, Hockerstedt K, Bjoro K. et al. The nordic multicenter double-blind randomized controlled trial of prophylaction UDCA in liver transplant patients.// Transplantation 1997;63: 1594-4

151. Kelly-Oxford D.A. Disease of the liver and biliary system in children.// Blackwell Science. 1999JP.432

152. Kerr J. F.R. A histochemical study of hypertrophy and ischemic iniury of rat liver.// J. Pathol.Bacteriol. 1965-90- P.419-423

153. Kerr J.F.R., Willie A.H., Currie A.R. Apoptosis: a basic biological phenomen with wide-rinding implications tissue kinetics. //Brit. J Cancer—1972-26-p.239-257

154. Kimura T, Shimamura M,.Iamaguchi A, Katajama T, Kirita T, Tanaka. Solubilisation of cultured cell membrane by bile acids(in Iapan).// Acta Hepatol Ipn 22(1) 1989,1-7

155. Kitani K. Hepataprotective effect of UDCA in experimental animals.//Abstr. Fair Symposium No 53; J Int Lugano Symposium on biliary Physiology and Disease: Strategies for the Treatment of Hepatobiliary Diseses, Lugano,Iune 15-17, 1989, 14

156. Kitani K. UDCA of cholestatic diseases (Letter to the Editor).// Lancet 11(8601) 1988;49

157. Kocak N, Saltik I.N. The effect of UDCA in children with prolonged hepatitis A virus invection that may be a trigger factor for autoimmune hepatitis.// Amer.J of Gastroenterol. 96(2) 2001,610-611

158. Koga Y. Anticholestatic and cytoprotective properties of UDCA- Studies in vivo and in vitro (in lap).// Acta Hepatol. Ipn.28 (2) 1987, 1597-1604

159. Kountouras I, Zaros C, Chatzopoulos D. Apoptosis in hepatitis C.// J Viral Hepat.2003, Sept.l0(5);335-42

160. Koyama A.H, Adachi A, Irie H. Physiological significance of apoptosis during animal virus infection.// Int Rev Immunol. 2003 Sep-Dec;22(5-6):341-59

161. Krahenbuhl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria.// J Hepatology 1993; 19:471-9

162. Kren B.T, Rodrigies C.M.P, Setchell K.D.R, Steer CI. Modulation of steady-state messenger RNA levels in the regenerating rat liver with bile acid feedig.// Liver Transplantation 7(4) 2001,321-334

163. Kronenberger В, Wagner M, Herrmann E, Mihm U, Piiper A, SarrazinC, Zeuzem S. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis CM J Viral Hepat. 2005 May;12(3):307-14

164. Kulka M., Chen A. et al. The cytophicl8fstrain of Hepatitis A virus induces RNA degradation in Frhk4 cells.// Archives of Virology Volume 148, N7,Yune 2003 P:1275-1300

165. Kurktschiev D, Temelrova-Kurktschiev T, H От K, Schentke K. Successful immunomodulating in AIDS patients with UDCA- a pilot study.// Clin Exp Immunol 1999 JAN; 115(1) 144-6

166. Kurtz W. Therapeutic effects of UDCA on the and gastrointestinal tract.// Freiburg, 1992.P.41

167. Lambreht W, Whitington P.F. Cholestatic liver diseases in children.// Current Science for Hospital and Practice .Cholestatic liver disease in children and adults. Hamburg ,Januari 25-6,1996,p.2-3

168. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico S.D, Giamberardino M.A, Cucurullo F. Antioxidant properties of UDCA .// Biochemical Pharmacol 64(11)2002,1661-1667

169. Lapinski T.W. The concentration of sFas-L, ICE and IL-lbeta in the serum and the liver tissue of chronic HCV infected patients.// J Hepatogastroenterology 2005, Sep.-Oct., 52(65): 1479-83

170. Lascus Т., Radkowski M., Wang L.F. Detection and seguence analysis of hepatitis В virus integrations in peripheral blood mononuclear cells.// J Virol 1999, 73(2):1235-8.

171. Lazaridis K.N, Gores G.J, binder K.D. UDCA mechanisms of action and clinical use in hepatobiliary disorders.// J Hepatol 2001;35:134-46

172. Leuschner U. UDCA influences immune parameters in patients with primary biliary cirrhosis.// Hepatology-1990. Vol.12, p.957

173. Leuschner U. UDCA therapy in primary biliary cirrhosis.// XI1 International Bile Acid Meeting: Falk Symposium №68. Basel 1992. P.46-47

174. Leuschner U. et al . Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up.//Dig Dis Sci/1985. Vol.-30. P-642-649

175. Leuschner U. et al. Cholestasis liver disease in adult.// New aspects in hepatology and gastroenterology: Falk Symposium №108. Tbilisi, 1998. P-39-41

176. Leuschner U. et al. Gallstone dissolution in patients with chronic active hepatitis.// Gastroenterology. 1981.Vol.80. P. 1208

177. Leuschner U., Fischer H., Kurtz W. et al. UDCA in primary biliary cirrhosis: results of controled double blind trial.// J Gastroenterology 1989; 97; 1268-74

178. Li C.P, Tong M.J, Hwang SJ, Luo J.C, Co R.L, Tsay S.H, Chang F.Y, Lee S.D.Autoimmune cholangitidis with features of autoimmune hepatitis.Successful treatment.// J of Gastroenterology and Hepatology15(1) 2000, 95-98

179. Lim A.G, Ahmed U.A, Jazrawi R.P, Northfield T.C. Effects of bile acids on human hepatic mitochondria.// Eur J Gastroenterol Hepatol 1994; 6:1157-63

180. Lindbland A, Glaumann H, Houweri B. A two-year prospektive study of the effect of UDCA on urinari bile acid escretion and liver morvology in cystic fibrosis-associated liver disease.// J Hepatology 1998;27 166-174

181. Lirussi F, Becarello A, Bortolato L, Morselli-Labate A.M, Crovatto M, Ceselli S, Santini G, Crepaldi G. Long-term treatment of chronic hepatitis С with UDCA:influence of HCV genotypes and severity of liver disease.// J Liver 1999,Oct. 19(5)3 81-388

182. Lo S.K, Hermann R, Chapman R.W. et al. UDCA in primary sclerosing cholangitidis: a double-blind placebo controlled trial.// J Hepatology 1992; 17:92

183. Loria P., Carulli N, Medici G. et al. Determinants of bile secretion: effect of bile salt strukture on bile flow and biliary cation secretion.// J Gastroenterology, 1989;96: 1142

184. Lowin D., Hahne M., Mattmann C.et al. Cytolytic T-CELL cytotoxycity is mediated through perforin and FAS litic pathways. //Nature-1994-370-P.650-652

185. Lu C.L, Chan C.Y, Hwang S.J, Lu R.H, Lee S.D. Efficacy of UDCA in the treatment of patients with hepatitis C.//J Gastroenterol Hepatol. 1995 jul-aug; 10(4)432-7

186. Lynne W., Elmare, Amy R. et al. Hepatitis В virus X protein and p53 tumor suppressor interactions in the modulations of apoptosis.// Medical Sciences 1997. Dec.23, 94(26). P. 14707-14712

187. Maggiore G, de Giacomo C. Efficacy of UDCA in preventive cholestatic episodes in a patient with benign recurrent intrahepatitc cholestasis.// J Hepatology 1992; 16:504

188. Makino I, Shinozaki K, Yoshinok, Nakagawa S. Dissolution of cholesterol gallstones by UDCA. //Jpn J Gastroenterology 1975;72;690-702

189. Maniatis T. Catalisis by a multiprotein Jkappa В kinase complex.//Science 1997 278:828

190. Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, Cordiali-Fei P, BerardescaE. Cytokine profiles during infliximab monotherapy in psoriatic arthritis.// Br J Dermatol. 2005 Sep;153(3):531-6

191. Matsushita M, Nagasawa M, Sato Y, Soudo K, Kobayashi Y. «Primary sclerosing cholangitidis associated with Limy Bile and Acute Pancreatitis» J Pancreatology 2005 Jun. 28;(4-5):466-469

192. Meier P.J. The bile salt secretory polarity of hepatocytes.// J Hepatology, 1989;9;124 P

193. Meng L.J, Reyes H, Axelson M, Palma J, Hernandez J, Ribalta J, Siovall J. Progesterone metabolites and acids in serum of patients with intrahepatic cholestasis of pregnancy: Effect of ursodeoxycholic acid therapy.// Hepatology 26(6) 1997, 15731579

194. Merhjian H.S, Phillips S.F,. Hofman A.F. Colonic absorption of unconjugated bile acids: perfusion studies in man. // Dig Dis Sci 1979;24:545-50

195. Mitchel С., Mallet V., Guidotti J.E., Mignon A., Couton D., Khan A., Gikgenkratz H. Experimental modulation of apoptosis: physiopathological and therapeutical targets.// J Soc Biol, 2005; 199(3): 243-6. Institut Cochin Department de Genetique

196. Mijayi K, Ariyama T, Ito M. et al. The effect of ursodeoxycholic acid on liver functions in patients with chronic liver disease: a double blind study in one institution and the effect on hepatic blood flow.// Rinshoto Kenkyu, 1976;53:1395-403

197. Mcllroy D.,Theodorou J.,Ratziu V.,Vidaud D.,Pellet P., Debre P., Poynard T. Fas promoter polymorphisms correlate with activity grade in hepatitis С patients.// Eur J Gastroenterol Hepatol., 2005 Oct; 17(10): 1081-1088

198. Mitsuyoshi H, Nakashima T, Sumura Y, Yoh T, Nakajima, Ishikawa H UDCA protects hepatocytes against ixydative injure via induction of antioxidants.// Biochemical and Biophysikal Research Communications 263(2) 1999, 537-542

199. Montet A.M, Oliva L, Beauge F, Montet J.C Bile salts modulate chronis ethanol-unduced hepatotoxicity. //J Alcohol Alcohol, 2002 Jan-Feb;37(l) 25-9

200. Mutluay R, Ozenirler S, Poyraz A. The expression of bcl-2 in chronic liver, diseases.// Saudi Med J. 2005 Aug;26(8): 1245-9

201. Nagata S. Apoptotic DNA fragmentation.// Exp Cell Res. 2000 Apr. 10; 256 (l):12-8

202. Naismismith J.H., Divine T.Q., Kohno T. Structures of the extracellular domain of the type I tumor necrosis factor receptor. // J. Structure 1996, 4:125

203. Nakashima T, Yoh T, Sumida Y, Kakisaka Y, Mitsuyoshi H. Differences in the efficacy of UDCA and bile acid metabolism between viral liver diseases and primary biliary cirrhosis. // J Gastroenterol Hepatol.2001 May;16(5):541-7

204. Nakayma F., Miyazaki K, Koga A. Effect of chenodeoxycholic and UDCA on isolated human hepatocytes.// J Gastroenterology 78 (part 2) 1980,1228

205. Narisawa T, Fukaura Y, Takeba N, Nakai K. Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats.// Japanese J of Cancer Research 93(2), 143-150

206. Narkewicz M.R, Smith D, Gregory C, Lear J.L, Osberg I, Sokol R.J. Effect of UDCA therapy on hepatic function in children with intrahepatic cholestatic liver disease.// J of Pediatric Gastroenterol and Nutrition 26(1)1998, 49-55

207. Nasir T, Arona H.S, Kaiser H.E. Apoptosis and pathogenesis of viral hepatitis C-an update.// in vivo.2002.Vol.l4.p.297-300

208. Nittino H., Tokita A, Hayashi M et al. UDCA therapy in the treatment of biliary atresia. // Biomed Pharmacother 1989:43:37-41

209. Odeh M, Oliven A. Treatment of prolonged cholestasis of acute hepatitis В with UDCA.// Hepatology Research 13(1)1998, p.37-41

210. Okuda M, Li K, Beard M.R. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced hepatitis С virus core protein//Gastroenterology 2002, 122(2),366-375

211. Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H. Reduction of hepatocarcinogenesis by UDCA in rats.// J Carcinogenesis 2002,May;23(5):885-92

212. Ozturk Y, Soyal C, Lebe B. Drug reaction to UDCA: Lichenoid drug eruption in infant using UDCA for neonatal hepatitis case report.// J of Pediatr Gastroenterology and Nutrition 35(3) 2002,384-386

213. Panasiuk A, Prokopowicz D, Dzieciol J, Adamski M The apoptosis of hepatic tissues in hepatitis C.// J Epidemiol. 2005;59(2):415-21.

214. Papakyriakou P, Tzardi M, Valatas V, Kanavaros P, Karydi E, Notas G,Xidakis C, Kouroumalis E. Apoptosis and apoptosis related proteins in chronic viral liver disease.// J Apoptosis.2002Apr;7(2): 133-41

215. Parguet M, Metman E.U, Raisman A, Raumband J.C. et al. Bioavailability, gastrointestinal transit, solubilisation and faecal excretion of UDCA in man.// EUR. J Clin Invest 1985;15:171-8

216. Park J.N., Choe K.W. P53 and p21WAFl/CIPI in hepatitis В virus hepatocarcinogenesis.// Hepatogastroentorology 2003r.Sep-C)ct 50(53): 1292-6

217. Paumgartner G, Beuers U. UDCA in cholestatic liver disease: mechanisms of action and therapeutic use revisited.// J Hepatology 36(3) 2002;525-531

218. Perez M.J, Macias R.I, Marin J.J. Maternal cholestasis induces placental oxidative stress and apoptosis Protective effect of ursodeoxycholic acid.// Placenta. 2006 Jan; 27(1):34-41

219. Persson H, Friman S, Schersten T, Svanvik I, Kallberg I. Adjuvant treatment with UDCA reduces acute rejection after liver transplantation.// Transplant Proc 1992; 24:389-90

220. Pgeaux G.P, Blac P, Ferrigault P.F. et al. Failure of UDCA to prevent acute cellular rejection after liver transplantation.// J Hepatology 1995; 23:119-22

221. Plevris J.N, Hayes P.C, Bouchier J.A.D. UDCA in the treatment of alcoholic liver disease.// Eur J Gastroenterology, Hepatology 1991:3:653-6

222. Pos E, Navarro S, Bru C, Gilabert R, Bianchi L, Buguera M UDCA treatment of primary hepatolithiasis in CArolis syndrome.//Lancet 1993; 342;404-6

223. Poupon R, Chretien Y, Poupon R.E, Ballet F, Calmus Y.D Amis F. Is ursodeoxycholic acid effective treament for primary biliary cirrosis?// Lancent, 1987;1:834-6

224. Poupon R, Poupon R.E. UDCA therapy of chronic cholestatic conditions in adults and children.// Pharmacol Ther.1995 Apr;66(l):l-15

225. Raghuraman S., Abraham P., Daniel H.D., Ramakrishna B.S., Sridharan G. Characterization of soluble Fas, Fas-ligand and TNF-alpha in patients with chronic HCV infection.// J Clin Virol 2005 Sep; 34(l);63-70

226. Rajesh KG, Suzuki R, Maeda H, Yamamoto M, Yutong X, Sasaguri S. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway.// J Mol Cell Cardiol. 2005 Nov;39(5):766-76. Epub 2005 Sep 19

227. Rifain E.L, Gottrand F. Role of UDCA in pediatric cholestatic disease.// Gastroenterol Clin Biol.2004 Oct; 28(1 Opfl): 852-9

228. Roberts L.R, Bronk S.F, Gores G. Effector proteases in bile salt-induced hepatocyte apoptosis.//Bile acids in Hepatobiliary Diseases. 1997, 265-271

229. Rodda E, Mazella G, Bazzoli F et al Effect of UDCA administration on biliary lipid secretion in primary biliary cirrihosis.//Dig Dis Sci 1989;34:528-88

230. Rodrigues C.M.P, Fan G.S, Ma X.M, Kren B.T, Steer C. A novel role for UDCA in inhibiting apoptosis by modulating mitochondrial membrane perturbation.// J of Clinical Investigation 101(12) 1998,2790-2799.

231. Rodrigues C.M.P,.Fan G.S.,.Wong P.Y, Kren B.T, Steer C. UDCA may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxigen species production.// J Molekular Medicine 4(3)1998, 165-178

232. Rosenthal P. Digestive disease week 2000. American Association for the Study of Liver Diseases.//IDrugs. 2000 Aug;3(8):868-71

233. Rosman A.S. Efficacy of UDCA in the treating bile reflux gastritis.// J Gastroenterology 1987; JAN.92(1):269

234. Roy M.K, Takenaka M, Kobori M, Nakahara K, Isobe S, Tsushida T Apoptosis, necrosis and cell proliferation-inhibition by cyclosporine A in U937 cells (a human monocytic cell line).// J Pharmacol Res.2006 Mar;53(3):293-302.;

235. Rubbia-Brandt L., Taylor S., Gindre P. Lack of in vivo blockade of FAS-and TNFR1 -mediated hepatocyte apoptosis by the hepatitis С virus.//J Pathol 2002 Aug., 197:617-23

236. Rui E, Moura P.R, Goncalves KA, Rooney R.J, Kobarg J. Interaction of the hepatitis В virus protein HBx with the human transcription regulatory protein pl20E4F in vitro. Virus Res. 2005 Aug 19; Epub ahead of print.

237. Sacco R., Tsutsumi Т., Suzuki R. et. al. Antiapoptotic regulation by hepatitis С virus core protein through up-regulation of inhibitor of caspase-activated Dnase.// Virology.2003 .Dec.5,317( 1 ):24-35

238. Sauerbruch T, Paumgartner G Therapy der cholelitiasis.// Internist.-1986-n.27.S.64

239. Scarpa P.J, Cappell M.S, Chen W.Y., Lao W. Treatment with UDCA of bile reflux gastritis after cholecystectomy.// J Clin Gastroenterology 1991 Oct; 13(5):601-3

240. Schomerich J, Miyal K, Baumgartner U, Gerok W. UDCA prevents taorolitocholate induced cholestasis in rat liver.// J Hepatol. 78 (suppl 1) 1988,A-147

241. Sharara AJ, Camargo CA, Clavien P.A. UDCA prevents rejection in liver transplant recipient.// Gastroenterol, 1995; 108(suppl):l 168 A

242. Shi Gekasi Nagata. Apoptosis. // J Cell 1999

243. Shoda M. Uber die Ursodeoxycholsaure aus Barengallen und ihre physiologische Wirkung. // J Biochem 1927:7;502-10

244. Silva R.F.M. Rodrigues C.M.P , Brites D. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic but prevented by UDCA.// J of Hepatology 34(3)2001,402-408

245. Smith J.L, Liwindon P.J, Hoskins A.C, Pereira T.N. Endogenous UDCA and cholic acid in liver disease due to cystic fibrosis.// Hepatology 2004 Iun; 39(6), 167382

246. Sokal E. Treatment of pediatric chronic hepatitis B-new millenium.// EASL 2001. APR, 18-22.P.68-69

247. Sola S, Brito M.A. Brites D, Moura J.I.G, Rodrigues C.M.P. Membrane structural changes support the involvement of mitochondrial in the bile salt-induced apoptosis of rat hepatocytes.//Clinical Science 103(5) 2002, 475-485

248. Spagnulo M.N, Jorio R, Vegnente A, Guarino A. UDCA for the treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study.// J Gastroenterology 1996; 111 :716-16

249. Stefaniwskiy A.B, Tint G.S, Speck J, Saden G, Shefer S . UDCA treatmen of bile reflux gastritis.// J Gastroenterology 1985 89;1000-1004

250. Stephen P.D., Murphy P. et al. Mutations within the 5Nontranslated Region of Hepatitis A Virus RNA which Enhance Replication in BS-C-1 cells.// Journal of Virology, Nov. 1992 p.6533-6540

251. Stiehl A, Raedsch R, Rudolph G. Acute effects of UDCA and henodeoxycholate acid on the small intestinal absorbtion of bile acids.// J Gastroenterology, 1990;98:424

252. Stiehl A, Waker S, Stiehl L. et al. Effect of UDCA on liver and bile duct disease in primary sclerosing cholangitidis a 3-year pilot study with a placebo-controlled study period.// J Hepatology, 1994;20:57

253. Stiehl A. Bile acid therapy in primary sclerosing cholangitidis.// Proc.Basel Liver Week,Oct. 17/18, 1995, 52

254. Stiel A, Walker S, Stiel L. et al. Effect of UDCA on liver and bile duct disease in primary sclerosing cholangitidis. A 3-year pilot study with a placebo- controlled study period.// J Hepatology 1994;20:57-64

255. Strand S, Hofman W.J, Hug H. Limphocyte apoptosis induced by CD95(AP01/Fas) ligand-expressing tumor celll- a mechanisms of immune evasion.// J Nat Med 1996;2:1361-6

256. Tazuma S, Kajijama G, Mizuno T, Yamashita G. A combinaton therapy with simvastatin and UDCA is more effective for cholesterol gallstone dissolution that is UDCA monotherapy.// J of Clinical Gastroenterology. 26(4) 1998,287-291

257. Tewari, Telford W.G., Miller R.A., Dixit V.M. Crm A, a poxvirus-encoded serpin, inhibits cytotoxicT-lymfocyte-mediated apoptosis.// J Biol.Chem. 1995. 270:22705-227-08

258. Thompson C.B. Apoptosis in the pathogenesis and treatment of diseases.// J Science 267: 1456, 1995.

259. Tint G.S, Salen G, Colatillo A. et al. UDCA: a safe and effective agent for dissolving cholesterol gallstones.// Arm Item Med 1982:97:351-6

260. Torzke G., Essmann F., Pohlmann S, Lindenblatt C., Javicke RU.,Schulze-Osthoff K. A novel member of the Jkarra В family, human Jkarra B-zeta, inhibits transactivation of p65 and its DNA binding.// J Biom.Chem 2006 Mar 2. Institut of Molecular Medicine

261. Trauner M., Graziadei I.W. Review article: mechanisms of UDCA action and therapeutic applications of UDCA in chronic liver diseases.// Alimentary Pharmacology and therapeutics 13(8) 1999, 979-995

262. Tsamandas A.C., Thomopolas K.et al. Expression of bcl-2 oncoprotein in cases of acute and chronic viral hepatitis type В and type C: a clinicopathologie study .//Did Did Schi 2002Yul

263. Tse-Ling Fong, Di Bisceglic A.M. et al. High levels of viral replication during acute hepatitis В infection predict progression to chronicity.//J Med. Virol. (1994) 43, 155-158

264. Tsubakio K, Kiriyama K, Matsushima N, Taniguchi M, Shizusawa T, Katon T.et al. Autoimmune pancreatitis successfully treated with UDCA.// Intem/Med.2002.Dec. 41(12): 1142-6

265. Ullrich D, Roting D, Schrote W, Hanefed F, Bircher J. Treatment with UDCA renders children with biliary atresia suitable for liver transplantation.// Lancet, 1987;2:1324

266. Vajro P, Franzece A, Valerio G, Iannucei M.P, Aragione N. Lack of efficacy of UDCA for the treatment of liver abnormalities in obese children.// J of Pediatric 136(6) 2000,739-743

267. Van Thiel D.N, Wright H.J, Gavaler J.S. UDCA therapy for primary sclerosing cholangitidis (PSC):preliminary report of a randomized controlled trial.// L Hepatol. 1992; 16:62a

268. Vendemiale G, Grattagliano J, Signorile A, Altomare E. Ethanol-unduced changes of intracellular thiol compartmentation and protein redox status in the rat liver: Effect of tauroursodeoxycholate.// J Hepatol 1998; 28; 46-53

269. Webb S.J. et al. Apoptosis. An overview of the process and its relevance in disease. //Adv Pharmacol 1997, 41:1

270. Whitington P.F. Cholestasis associated with total parenteral nutrition in infants.// J Hepatology 1985;5:693-6

271. Yagura M, Murai S et al. Parameters predicting response to UDCA in chronic hepatitis CM J Hepatology Research 14(1); 1999; 18-25

272. Yamanaka M, Oto M, Obata H. et al. The examenation of the therapeutic efficacy of UDCA on chronic hepatitis. A double blind study.// Shindan to Chiryo 1976;64:2150-7

273. Yochikawa M, Tsujii T, Matsumara K, Yamao J, Matsumura Y, Kubo R. et al. Immunomodulatory effects of UDCA on immune responses.// J Hepatology, 1992, 16:358-64

274. Younossi Z.M, Perillo R.P. The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.//Semin Liver Dis.1999 suppl 1:95-102

275. Yue Fe, Liu D.Y, Song J, Zhang L.N. Soluble tumor necrosis factor related apoptosis inducing ligand (sTrail) and clinical outcome of HBV infection in human.//Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2005. Jun; 19(2): 146-8

276. Zhang H., Chao C.F., Ping L.H. et al. An infections Cdna clone of a cytopathic hepatitis A virus: genomic regions associated with rapid replication and cytopathic effect. //J Virology 1995 Oct.l,212(2):686-97

277. Zhang S.J, Chen H.Y, Chen Z.X, WangX.Z. Possible mechanism for hepatitis В virus X gene to induce apoptosis of hepatocytes.// World J Gastroenterol. 2005 Jul 28;11(28):4351-6

278. Zukowski T.H, Jorgensen R.A, Dickson E.R, binder K.D. Autoimmune conditions associated with primary biliary cirrhosis: Response to ursodeoxycholic acid therapy.// American J of Gastroenterology 93(6) 1998, 958-961